|
|
|
European Biopharmaceutical Review
|
|
Antibodies have been a major focus in biopharmaceutical research and development for the last two decades, ever since the first development of a process for the isolation of monoclonal antibodies (mAbs) in the 1970s. Following the FDA approval of the first therapeutic mAb in 1986 (1), and as a result of significant technological advances in the 1990s, mAbs and antibody fragments are now an increasingly important class of drugs. Reports from 2008 indicate that there are currently over 200 mAb candidates in clinical development (2), with 24 mAbs having been approved for therapeutic use (1).
Therapeutic antibodies in clinical use today cover a broad range of indications, including cancer, chronic inflammatory diseases, transplant rejection, infectious diseases and cardiovascular disease. The majority of antibody drugs are full-sized IgG forms, although there is increased interest in the use of antibody fragments, with three fragment-based drugs being approved for therapeutic use in the US.
ANTIBODY CLASSES, STRUCTURE AND FUNCTION
Human antibodies are grouped into five different isotypes (IgG, IgE, IgD, IgM and IgA) and then split further into sub-classes (IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) (see Figure 1). The different isotypes have distinct functions within the body.
Antibodies are relatively large globular proteins, consisting of two heavy chains (which define the isotype and subclass) and two light chains. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Dr Frank Detmers is Director of Ligand Application at BAC. In 2001, he received his PhD at the department of Molecular Microbiology at the University of Groningen (the Netherlands). He worked as a postdoctoral researcher at the Department of Cell Physiology at the Nijmegen Center of Molecular Life Sciences (NCMLS, Nijmegen, the Netherlands). He joined BAC in 2004 and the focus of his work is immobilisation of affinity ligands on solid supports and the development of applications of ligands in healthcare.
After receiving a Bachelors degree in Biochemistry, Pim Hermans joined the R&D department at Holland Biotechnology. In this group, he carried out research on the production and purification of recombinant cytokines and monoclonal antibodies for diagnostic and research purposes. In 1993, Pim joined the Bio-Immunochemistry group at Unilever-Bestfoods, where he was involved in the early development and exploration of camelid derived single domain antibodies (VHHs). Pim joined BAC in 2002. As Director of the Ligand Discovery Department, Pim is responsible for the development of VHH-based affinity ligands for applications in process, and analytical affinity chromatography. |
|
|
|
|
|
 |
News and Press Releases |
 |
MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development
MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >> |
|
 |
White Papers |
 |
|
Digital Transformation of the Cold Chain
Sensitech EMEA
The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >> |
|
 |
Industry Events |
 |
Multimodal 2019
18-20 June 2019, NEC, Birmingham, UK
Now in its twelfth year, Multimodal is the UK
and Ireland’s premier freight transport, logistics and supply chain
management event. Shippers and cargo owners attend to improve their
businesses; by finding ways of moving their products
more efficiently and by meeting new suppliers.
More info >> |
|
|
